Montelukast Teva Uk (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Teva Uk, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Teva Uk belongs to the leukotriene receptor antagonist class and is indicated for several respiratory allergic conditions.

- Asthma: provides maintenance therapy that reduces the frequency and severity of asthma attacks. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: persistent dry cough. - Nausea: feeling of queasiness. - Dizziness: light‑headed sensation. - Fatigue: unusual tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: increased liver function tests. - Hematologic effects: leukopenia or neutropenia. - Severe skin reactions: Stevens‑Johnson syndrome. - Respiratory distress: worsening bronchospasm despite therapy.

Before initiating therapy, certain precautions should be considered.

- Liver function monitoring: check hepatic enzymes periodically, especially in patients with liver disease. - Psychiatric assessment: observe for mood alterations or suicidal ideation. - Hypersensitivity: avoid use in individuals with known allergy to montelukast or any component of the tablet. - Severe hepatic impairment: use with caution and consider alternative therapy. - Renal impairment: dose adjustment is generally not required but monitor clinical response. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: induces metabolism and may lower montelukast plasma levels. - Rifampin: strong enzyme inducer that can decrease therapeutic effect. - Ketoconazole: potent CYP3A4 inhibitor that may raise montelukast concentrations.

Moderate Interactions (Monitor Closely): - Beta‑agonists: additive bronchodilator effect may increase risk of tachycardia. - Warfarin: possible alteration of INR; monitor coagulation parameters. - NSAIDs: may increase gastrointestinal irritation when combined with montelukast.